Scleroderma is an autoimmune disease characterized by the overproduction of collegen and other fibrotic cells. This overproduction generally first appears on the skin, although it can also express systemically.
Featured articles on Scleroderma
When you cut yourself and start to heal, your body forms a matrix of tissue largely composed of collagen. It’s the basis of the scar tissue that forms where the cut was. For people with scleroderma, a rare auto-immune disease, their tissues continue developing even without an injury, resulting in the overproduction of collagen and other fibrous tissues, called fibroblasts, in the skin and... Read more
Science abstracts on Scleroderma
- The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways.
- VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.
- Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis.
- Cannabis sativa as a Potential Treatment for Systemic Sclerosis.
- Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System.
- Medical cannabis: Another piece in the mosaic of autoimmunity?
- The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders.
- Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic Sclerosis
- Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1.
- Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts.
- EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis.
